417 related articles for article (PubMed ID: 25029933)
1. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.
Panagiotidis E; Bomanji J
PET Clin; 2014 Jan; 9(1):43-55. PubMed ID: 25029933
[TBL] [Abstract][Full Text] [Related]
2. 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.
Minn H; Kemppainen J; Kauhanen S; Forsback S; Seppänen M
PET Clin; 2014 Jan; 9(1):27-36. PubMed ID: 25029931
[TBL] [Abstract][Full Text] [Related]
3. Single-photon emission computed tomography tracers in the diagnostics of neuroendocrine tumors.
Pepe G; Bombardieri E; Lorenzoni A; Chiti A
PET Clin; 2014 Jan; 9(1):11-26. PubMed ID: 25029930
[TBL] [Abstract][Full Text] [Related]
4. PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
Shamim SA; Kumar A; Kumar R
PET Clin; 2015 Jul; 10(3):411-21. PubMed ID: 26099675
[TBL] [Abstract][Full Text] [Related]
5. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract][Full Text] [Related]
6. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
[TBL] [Abstract][Full Text] [Related]
7. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
[TBL] [Abstract][Full Text] [Related]
8. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
9. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers.
Jadvar H
Semin Nucl Med; 2012 Jul; 42(4):247-54. PubMed ID: 22681673
[TBL] [Abstract][Full Text] [Related]
11. Clinical Usefulness of
Rinzivillo M; Partelli S; Prosperi D; Capurso G; Pizzichini P; Iannicelli E; Merola E; Muffatti F; Scopinaro F; Schillaci O; Salgarello M; Falconi M; Delle Fave G; Panzuto F
Oncologist; 2018 Feb; 23(2):186-192. PubMed ID: 29118267
[TBL] [Abstract][Full Text] [Related]
12. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
Berends AMA; Kerstens MN; Bolt JW; Links TP; Korpershoek E; de Krijger RR; Walenkamp AME; Noordzij W; van Etten B; Kats-Ugurlu G; Brouwers AH; van der Horst-Schrivers ANA
Eur J Endocrinol; 2018 Aug; 179(2):125-133. PubMed ID: 29875288
[TBL] [Abstract][Full Text] [Related]
13. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
[TBL] [Abstract][Full Text] [Related]
14. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
15. Other PET tracers for neuroendocrine tumors.
Koopmans KP; Glaudemans AW
PET Clin; 2014 Jan; 9(1):57-62. PubMed ID: 25029934
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Prognostic Value of PET/CT Imaging with Combination of
Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M
Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
[TBL] [Abstract][Full Text] [Related]
17. Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: fluorodeoxyglucose and nonfluorodeoxyglucose tracers.
Wong KK; Arabi M; Zerizer I; Al-Nahhas A; Rubello D; Gross MD
Nucl Med Commun; 2011 Sep; 32(9):764-81. PubMed ID: 21799367
[TBL] [Abstract][Full Text] [Related]
18. Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report.
Lorusso M; Inzani F; Castaldi P; Menghi R; Schinzari G; Rindi G; Rufini V
Pancreas; 2018 Apr; 47(4):e20-e22. PubMed ID: 29521949
[No Abstract] [Full Text] [Related]
19. The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (
Lung MS; Hicks RJ; Pavlakis N; Link E; Jefford M; Thomson B; Wyld DK; Liauw W; Akhurst T; Kuru N; Michael M
Asia Pac J Clin Oncol; 2020 Jun; 16(3):150-157. PubMed ID: 32030887
[TBL] [Abstract][Full Text] [Related]
20. Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT).
Hofman MS; Michael M; Kashyap R; Hicks RJ
J Nucl Med; 2015 Jun; 56(6):968-9. PubMed ID: 25814516
[No Abstract] [Full Text] [Related]
[Next] [New Search]
